The influence of morning versus evening administration on tamoxifen pharmacokinetics.
- Conditions
- Breast Cancer (borstkanker)
- Registration Number
- NL-OMON28836
- Lead Sponsor
- Erasmus MC ¨C Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, the Netherlands
- Brief Summary
Binkhorst et al. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Res Treat 2015;152(1):119-28
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 18
Inclusion Criteria
1. Histological or cytological confirmed diagnosis of breast cancer, for which treatment with tamoxifen is indicated;
2. Use of tamoxifen for at least 4 weeks and willing to continue the treatment until the end of the study;
Exclusion Criteria
1. Pregnant or lactating patients;
2. Serious illness or medical unstable condition requiring treatment, symptomatic CNS metastases or history of psychiatric disorder that would prohibit the understanding and giving of informed consent;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determine differences in tamoxifen pharmacokinetics during tamoxifen administration in the morning compared to administration in the evening. <br>Amendment: Determine differences in tamoxifen pharmacokinetics during tamoxifen administration in the morning, afternoon and evening
- Secondary Outcome Measures
Name Time Method Determine differences in adverse effects during tamoxifen administration in the morning compared to administration in the evening.<br>Amendment: Determine differences in adverse effects during tamoxifen administration in the morning compared to administration in the afternoon and evening.